Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. It operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. It also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, the company provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. It provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Elevance Health Inc.

SELVA GIDA SANAYI A.S. ( ($TR:SELVA) ) just unveiled an announcement. Trading in SELVA.E shares has been temporarily suspended on Borsa Istanbul un...

SELVA GIDA Shares Temporarily Halted Under Circuit Breaker on Borsa Istanbul

The latest announcement is out from Elevra Lithium ( ($AU:ELV) ). Morella Corporation has declared a maiden JORC 2012 Inferred Mineral Resource Est...

Morella Unveils Maiden Rubidium Resource at Mt Edon Project

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Butterfly Network (BFLY) and Elevance Health (ELV) w...

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY) and Elevance Health (ELV)

Elevra Lithium ( ($AU:ELV) ) has provided an announcement. Elevra Lithium Limited has released the results of a Pre-Feasibility Study for a three-s...

Elevra Lithium Unveils High-Value Expansion Plan for Québec NAL Mine

Elevra Lithium ( ($AU:ELV) ) has provided an update. Elevra Lithium reported fiscal 2026 output of nearly 198,000 dry metric tonnes of product, sel...

Elevra Lithium flags fully funded expansion as North American hard-rock output grows

Elevra Lithium ( ($AU:ELV) ) has provided an announcement. Elevra Lithium has completed a pre-feasibility study for a three-stage brownfield expans...

Elevra Lithium’s Québec Expansion PFS Targets Doubling Output and Lower Costs

U.S. stocks finished Friday mixed after a stronger-than-expected August jobs report pushed Treasury yields higher and revived concerns that the Fed...

The Week That Was, The Week Ahead: Macro and Markets, September 6

In a report released yesterday, Reg Spencer from Canaccord Genuity maintained a Buy rating on Elevra Lithium, with a price target of A$17.80. Spenc...

Canaccord Genuity Keeps Their Buy Rating on Elevra Lithium (SYAXF)

Elevra Lithium Limited (($AU:ELV)) has held its Q4 earnings call. Read on for the main highlights of the call. Elevra Lithium’s latest earnings cal...

Elevra Lithium Earnings Call Signals Strength Amid Costs

In a report released today, Lance Wilkes from Bernstein assigned a Buy rating to Elevance Health, with a price target of $488.00. Wilkes covers the...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ELV	$396.09	-0.54%	1.17M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ELV	$396.09	-0.5%	1.17M
3
4
5
6

ELV

Get Elevance Health Inc. Data in Excel

Get Elevance Health Inc. Data in Excel